Physician profile
Michael Y Wang
NPI 1306847447
$15,297.62
in general payments reported to CMS, 2019-2025
47 companies · $1,106 in 2025
The $1,106 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,514 · 2020: $3,298 · 2021: $1,698 · 2022: $1,880 · 2023: $2,492 · 2024: $1,310 · 2025: $1,106.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,338 · Travel and Lodging: $570.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,338.27 |
| Travel and Lodging | $569.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic USA, INC. | $2,631.86 | 2019-2020 | |
| Amgen INC. | $1,665.02 | 2019-2025 | Repatha, Otezla, Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,116.70 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Pfizer INC. | $1,048.59 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $957.57 | 2019-2024 | Breztri, Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $867.23 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Novo Nordisk INC | $768.75 | 2019-2025 | Ozempic, Rybelsus, Tresiba |
| Stryker Corporation | $760.72 | 2023 | N/A, Yukon Oct Spinal System |
| Abbvie INC. | $666.53 | 2021-2025 | Vraylar |
| Astellas Pharma US INC | $552.88 | 2019-2021 | |
| Sumitomo Pharma America, INC. | $421.79 | 2023-2025 | Gemtesa |
| Lilly USA, LLC | $354.93 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Merck Sharp & Dohme LLC | $351.77 | 2019-2025 | Capvaxive, Gardasil 9, M-M-R II |
| Janssen Pharmaceuticals, INC | $332.08 | 2019-2024 | Xarelto |
| Amarin Pharma, INC. | $320.72 | 2019-2022 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.